Ubs Asset Management Americas Inc Cure Vac N.V. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 277,166 shares of CVAC stock, worth $795,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
277,166
Previous 302,296
8.31%
Holding current value
$795,466
Previous $1.03 Million
20.74%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CVAC
# of Institutions
93Shares Held
12.3MCall Options Held
164KPut Options Held
117K-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$6.94 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$6.47 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.5 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$2.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$2.24 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $538M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...